A Study of AK129 With or Without AK117 in PD(L)1-refractory Classic Hodgkin Lymphoma

This trial is testing a new treatment combination — AK129 (with or without AK117) — for people with classic Hodgkin lymphoma that has stopped responding to PD-1 or PD-L1 immunotherapy drugs. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with relapsed or refractory classic Hodgkin lymphoma - Your cancer has progressed after treatment with a PD-1 or PD-L1 checkpoint inhibitor - Your organ function is adequate - Your general health is good (ECOG 0-1) - Your expected survival is at least 12 weeks **You may NOT be eligible if...** - You have nodular lymphocyte-predominant Hodgkin lymphoma or gray zone lymphoma - Your lymphoma has spread to the brain or spinal cord - You have had a recent stem cell transplant or CAR-T therapy (within 90 days) - You have had an organ transplant or bone marrow transplant from a donor - You have active hepatitis B or C, or an active autoimmune disease - You have had prior treatment targeting the same immune pathways (CD47 or LAG-3) Talk to your doctor to see if this trial is right for you.